Cutting-Edge Nanodisc Technology Reveals HIV and Ebola Vulnerabilities
- Researchers at the Scripps Research Institute, in collaboration with the International Vaccine Institute (IAVI) and other partners, have developed a nanodisc-based platform that allows scientists to study viral...
- The findings, which were outlined in Nature Communications on February 10, 2026, address a long-standing challenge in vaccine development.
- Traditionally, researchers have relied on simplified, lab-made versions of viral surface proteins to observe how the immune system responds.
Researchers at the Scripps Research Institute, in collaboration with the International Vaccine Institute (IAVI) and other partners, have developed a nanodisc-based platform that allows scientists to study viral proteins in a form that closely mimics their natural state. This technology has revealed hidden interactions and weak spots in viruses such as HIV and Ebola that were previously missed using traditional laboratory methods.
The findings, which were outlined in Nature Communications on February 10, 2026, address a long-standing challenge in vaccine development. To create vaccines, scientists typically study the specialized proteins that coat the outer surfaces of viruses, as these are the primary targets for the immune system.
Overcoming the Limitations of Lab-Made Proteins
Traditionally, researchers have relied on simplified, lab-made versions of viral surface proteins to observe how the immune system responds. However, these versions often lack the critical sections of the proteins that normally sit within the virus’s outer membrane.
Because these lab-made proteins are missing these membrane-embedded components, they do not always behave the same way they would during a real infection. This discrepancy has made it difficult for scientists to understand how antibodies truly recognize and neutralize viral targets in a living host.
The new platform utilizes nanodisc technology to bridge this gap. By placing viral proteins into tiny particles made of lipid molecules, the researchers have created a setup that recreates the virus’s natural membrane environment.
This environment helps preserve the natural structure and behavior of the proteins, allowing researchers to see how antibodies actually attack the viruses in a more realistic setting.
Application to HIV and Ebola
The research team tested the nanodisc platform using proteins from HIV and Ebola. Both viruses have historically challenged vaccine developers because their surface proteins are difficult for the immune system to target effectively.
By using the nanodisc system, the team uncovered hidden interactions that traditional methods had overlooked. In the case of Ebola, the platform confirmed that antibodies could identify and bind to the viral proteins when they were held within the membrane-like environment.
William Schief, professor at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center
Our platform lets us study these proteins in a setting that better reflects their natural environment, which is critical if we want to understand how protective antibodies recognize a virus.
Broader Implications for Vaccine Design
Beyond structural studies, the nanodisc platform can be used to analyze the immune responses to various vaccine candidates. This capability could potentially speed up the development of more effective vaccines by providing a more accurate map of how antibodies interact with viral targets.
While the initial tests focused on HIV and Ebola, researchers suggest the approach could be applied broadly to other viruses that utilize similar membrane-embedded proteins. Potential candidates for this technology include:
- Influenza
- SARS-CoV-2
By recreating the membrane environment, scientists can better understand how immune defenses work and identify the most effective ways to prompt the body to produce neutralizing antibodies.